1. |
|
|
2. |
|
|
3. |
|
|
4. |
- Aage, Hans
(författare)
-
46. Trends in economic transition
- 2002. - 1
-
Ingår i: The Baltic Sea Region. - Uppsala : Baltic University Press. - 9197357987 ; , s. 591-600
-
Bokkapitel (populärvet., debatt m.m.)
|
|
5. |
- Aage, Hans
(författare)
-
50. EU enlargement
- 2001. - 1
-
Ingår i: The Baltic Sea Region. - Uppsala : Baltic University Press. - 9197357987 ; , s. 630-638
-
Bokkapitel (populärvet., debatt m.m.)
|
|
6. |
- Aage, Hans
(författare)
-
51. The environment
- 2002. - 1
-
Ingår i: The Baltic Sea Region. - Uppsala : Baltic University Press. - 9197357987 ; , s. 639-650
-
Bokkapitel (populärvet., debatt m.m.)
|
|
7. |
- Aahlin, Kristofer, et al.
(författare)
-
Preparation of 1-(4-(5-amino-6-(oxazolo[4,5-c]pyridin-2-yl)pyrazin-2-yl)benzoyl)piperazine derivatives as glycogen synthase kinase 3 inhibitors.
- 2011
-
Patent (populärvet., debatt m.m.)abstract
- Title compds. I [R1 = H or Me], and their pharmaceutically acceptable salts, are prepd. and disclosed as glycogen synthase kinase 3 (GSK3) inhibitors. Thus, e.g., II was prepd. by cyclization of 3-amino-N-(4-hydroxypyridin-3-yl)pyrazine-2-carboxamide (prepn. given) to get intermediate 3-(oxazolo[4,5-c]pyridin-2-yl)pyrazin-2-amine, which underwent bromination followed by Suzuki reaction with (4-methylpiperazin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone. Compds. of the invention were tested for their selective inhibitory activity of GSK3β, e.g., II exhibited Ki value of 2.3 nM. The invention compds. are useful for the treatment of cognitive disorders, diabetes, cancer, etc. [on SciFinder(R)]
|
|
8. |
|
|
9. |
- Abi Ghaida, Fatima, et al.
(författare)
-
Enzymatic N2 activation : general discussion
- 2023
-
Ingår i: Faraday discussions. - : Royal Society of Chemistry. - 1359-6640 .- 1364-5498. ; 243, s. 287-295
-
Tidskriftsartikel (populärvet., debatt m.m.)
|
|
10. |
|
|